Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Stem Cell Registry Approves 52 Genea Biocells hESC Lines

Published: Friday, February 21, 2014
Last Updated: Friday, February 21, 2014
Bookmark and Share
Company becomes world’s largest provider of hESC lines on the NIH Stem Cell Registry.

The approval of 52 of Genea’s hESC lines provides academic and commercial researchers with innovative cellular tools to drive the discovery of new treatments for serious genetic or acquired diseases including orphan diseases. Amongst the 52 stem cell lines listed with the NIH Stem Cell Registry are 43 disease-specific hESC lines representing 24 different genetic diseases. These genetic diseases include:

• neurodegenerative conditions such as Huntington’s disease, tuberous sclerosis and infantile neuroaxonal dystrophy; and

•neuromuscular disorders such as Charcot-Marie-Tooth disease, Becker muscular dystrophy, myotonic dystrophy and FSHD.

Also included are cell lines expressing genes coding for genetic cancers, metabolic conditions, vascular diseases and eye conditions. 

The nine unaffected cell lines approved are from varied genetic backgrounds. All cell lines are derived in full compliance with international ethical and regulatory standards.

Genea Biocells General Manager Uli Schmidt said the approval of the cell lines by the NIH is an acknowledgment of the Company’s expertise and leadership in this field and reflects the exceptionally high ethical standards under which Genea Biocells operates.

“These cell lines will give scientists across the world vital and adaptable platforms to find treatments, and hopefully cures, for some of the most devastating diseases humans face today,” Dr Schmidt said.

“These approvals make Genea Biocells the leader in the provision of normal and disease-specific human embryonic stem cell lines, ahead of any other institution or company in the world.”

Genea Biocells’ human embryonic stem cells are derived from embryos voluntarily donated by patients who have undergone in vitro fertilisation - often in conjunction with preimplantation genetic diagnosis (PGD) - at Genea’s fertility clinics.

Under the guidelines of the NIH Stem Cell Registry, all lines listed must have been derived from embryos that were created solely for reproductive purposes; excess to the reproductive needs of the donors; and must have been fully consented for stem cell derivation in a specific, fully informed and voluntary consent process. No financial or other inducements can be offered or made for embryo donation. Many Genea patients appreciate the option to donate to research embryos that are unsuitable or no longer required for their reproductive purposes. They see it as a valuable contribution to the greater good and a more meaningful alternative to discarding their embryos.

Embryonic stem cells are pluripotent, meaning that they have the potential to form any cell type of the human body and can replicate indefinitely. All other non-pluripotent types of stem cells have limitations with respect to the number of replications and the range of cell types they can form. Embryonic stem cells are considered the gold standard pluripotent cell type by the majority of scientists.

Genea Biocells has the world’s largest private bank of pluripotent human embryonic stem cells with more than 100 individual lines representing almost 30 different genetic diseases. NIH applications for remaining Genea Biocells cell lines are in preparation.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!